According to reports from four Reuters sources, AstraZeneca's vaccine trial in the U.S. could continue as early as this week.
The drugmaker's large, late-stage trial has been on hold since September 6, after a participant in the company’s UK trial reportedly contracted transverse myelitis, a rare spinal inflammatory disorder.
Sources also say that the FDA is requiring trial researchers to add information about the incident to consent forms signed by participants.
Read the Reuters report